| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maria Tzouvala, Eirini Zacharopoulou, Maria Kalafateli, Nikos Viazis, Andreas Psistakis, Angeliki Theodoropoulou, Ioannis Drygiannakis, Konstantinos Karmiris, Ioannis E Koutroubakis, Polyxeni Kevrekidou, Kostas Soufleris, Marios Katsaros, Olga Giouleme, Fotios Fousekis, Konstantinos Katsanos, Dimitrios Christodoulou, Aikaterini Gaki, Evgenia Papathanasiou, Giorgos Bamias, Evanthia Zampeli, Spyridon Michopoulos, Nikolaos Kyriakos, Christos Veretanos, Konstantinos Argyriou, Andreas Kapsoritakis, George Tribonias, Gerassimos J Mantzaris and Christos Liatsos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Christos Liatsos, Director, MD, PhD, Department of Gastroenterology, 401 General Military Hospital of Athens, Panagioti Kanellopoulou Ave, Athens 11525, Greece. cliatsos@yahoo.com |
| Key Words |
Ulcerative colitis; Tofacitinib; Extended induction; Predictors; Efficacy; Safety; Real-world study |
| Core Tip |
This multicenter, retrospective cohort study evaluated the effectiveness and safety of administering a 16-week extended induction protocol for tofacitinib in patients with moderate-to-severe ulcerative colitis. At week 52 over half of the patients achieved clinical remission with a drug persistence rate of 75.7%. Notably, prior exposure to biologics was associated with the need for continuous administration of escalated doses while active smoking was significantly associated with treatment discontinuation. Extended induction therapy in selected patients may be beneficial. Our study highlights the need for further research to identify predictors of long-term response and optimal dosing strategies. |
| Publish Date |
2025-11-13 06:51 |
| Citation |
<p>Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. <i>World J Gastroenterol</i> 2025; 31(42): 111282</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i42/111282.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i42.111282 |
